Semaglutide, tirzepatide and retatrutide are three compounds that have received considerable attention in modern metabolic research. While they are often discussed together, they are not identical.
The main difference comes down to how each compound interacts with hormone receptors.
Semaglutide primarily targets the GLP-1 receptor. Tirzepatide works through both GLP-1 and GIP receptors. Retatrutide goes a step further by targeting GLP-1, GIP and glucagon receptors.
This difference in mechanism is the reason retatrutide is sometimes described as a triple agonist and informally referred to as a “GLP-3” peptide.
But what does this actually mean, and how does a retatrutide GLP-3 pen compare with semaglutide and tirzepatide?
The Basic Difference Between the Three
The easiest way to compare the three compounds is to look at their primary receptor activity.
| Compound | Receptor activity | General research classification |
| Semaglutide | GLP-1 | GLP-1 receptor agonist |
| Tirzepatide | GLP-1 + GIP | Dual agonist |
| Retatrutide | GLP-1 + GIP + glucagon | Triple agonist |
These differences are important because GLP-1, GIP and glucagon are separate signalling pathways involved in glucose regulation, appetite, energy balance and metabolism.
The compounds therefore approach metabolic research from different angles.
What Is Semaglutide?
Semaglutide is a peptide-based compound that acts primarily on the GLP-1 receptor.
GLP-1, or glucagon-like peptide-1, is a naturally occurring hormone involved in glucose regulation and several other physiological processes.
Activation of the GLP-1 receptor can influence insulin secretion in a glucose-dependent manner, gastric emptying and appetite-related signalling.
Semaglutide has been extensively studied in clinical research and is now an established medicine for specific indications in several countries.
Its long history of research makes it useful as a reference point when looking at newer compounds.
From a mechanism perspective, however, semaglutide is relatively straightforward compared with tirzepatide and retatrutide because its primary target is the GLP-1 receptor.
What Is Tirzepatide?
Tirzepatide introduced another approach by combining activity at GLP-1 and GIP receptors.
GIP stands for glucose-dependent insulinotropic polypeptide. Like GLP-1, it is an incretin hormone involved in metabolic signalling.
Rather than relying on GLP-1 activity alone, tirzepatide interacts with both GLP-1 and GIP pathways.
This makes tirzepatide a dual receptor agonist.
The combination has made tirzepatide an important subject in metabolic research and has helped increase interest in multi-pathway compounds.
It also provides a useful comparison with retatrutide, because retatrutide retains GLP-1 and GIP activity while adding another receptor target.
What Is Retatrutide?
Retatrutide is an investigational peptide designed to activate three receptors:
- GLP-1
- GIP
- Glucagon
Because of this, it is classified as a triple agonist.
The addition of glucagon receptor activity is the major mechanistic difference between retatrutide and tirzepatide.
The term “GLP-3” is sometimes used to describe retatrutide in online discussions, but it should not be interpreted as meaning that GLP-3 is an established naturally occurring hormone. It is generally a shorthand reference to retatrutide’s three-pathway activity.
Retatrutide remains under clinical investigation, so its research status is different from that of approved medicines containing semaglutide or tirzepatide.
Retatrutide vs Semaglutide: What Is Different?
The biggest difference is the number of pathways involved.
Semaglutide primarily activates the GLP-1 receptor.
Retatrutide activates GLP-1, GIP and glucagon receptors.
This means researchers are investigating retatrutide as a broader multi-pathway approach rather than simply another GLP-1 receptor agonist.
That does not mean retatrutide should automatically be considered better than semaglutide.
The two compounds have different mechanisms, different clinical-development histories and different regulatory statuses. Direct comparisons also need to take into account the design and population of individual clinical trials.
One of the reasons retatrutide has attracted attention is that its additional GIP and glucagon activity may influence metabolic processes beyond those affected by GLP-1 receptor activation alone.
Retatrutide vs Tirzepatide: What Is Different?
The comparison between retatrutide and tirzepatide is particularly interesting because both involve GLP-1 and GIP activity.
The key difference is glucagon receptor activity.
Tirzepatide:
GLP-1 + GIP
Retatrutide:
GLP-1 + GIP + glucagon
This makes retatrutide a triple agonist, while tirzepatide is a dual agonist.
Glucagon plays an important role in glucose and energy metabolism. Researchers are therefore investigating whether adding glucagon receptor activity to GLP-1 and GIP signalling can produce a distinct metabolic profile.
This is one of the central scientific questions surrounding retatrutide.
Why Is the Glucagon Pathway Important?
Glucagon is sometimes discussed mainly in relation to its role in increasing blood glucose, but its biological role is broader than that.
It is involved in energy mobilisation and metabolic regulation, particularly during periods when the body needs to access stored energy.
This is why glucagon receptor activity is particularly interesting in the development of multi-receptor metabolic compounds.
Retatrutide combines this pathway with GLP-1 and GIP signalling.
The objective of research is to understand whether these pathways can complement one another when activated by a single molecule.
Does More Receptor Activity Mean Better Results?
Not necessarily.
It can be tempting to assume that a triple agonist must automatically outperform a dual agonist, which must automatically outperform a single agonist.
Biology is more complicated than that.
Each additional pathway can change both the potential effects and the potential tolerability of a compound. Researchers therefore need controlled clinical studies to determine whether a particular mechanism provides meaningful advantages.
The important question is not simply how many receptors a compound targets.
Researchers also need to consider:
- How strongly each receptor is activated
- How long the compound remains active
- Appropriate dosing
- Tolerability
- Adverse effects
- Long-term outcomes
- Differences between patient populations
For this reason, mechanism alone should not be used to determine which compound is “best”.
How Does the Research Compare?
Semaglutide has the longest-established research and clinical history of the three.
Its GLP-1 receptor activity has been extensively studied across multiple indications.
Tirzepatide subsequently expanded the field through combined GLP-1 and GIP receptor activity, with substantial clinical research examining its metabolic effects.
Retatrutide is newer and remains investigational. Clinical trials have generated significant interest in its effects on body weight and metabolic measures, but researchers are still evaluating its long-term profile.
This difference in research maturity is important.
A compound with years of clinical data cannot be evaluated in exactly the same way as an investigational compound that is still progressing through clinical development.
What About a Retatrutide GLP-3 Pen?
The term GLP-3 pen generally refers to a pen-style presentation of a retatrutide product.
The delivery format itself does not change the pharmacology of retatrutide. What matters scientifically is the active compound, its formulation, concentration and quality.
This is particularly important when comparing research products with approved pharmaceutical products.
A research-use product should not automatically be assumed to have the same manufacturing standards, formulation or regulatory status as an approved medicine.
For example, products marketed by suppliers such as Research Peptides UK may be presented for laboratory or research purposes, but product descriptions should always be considered separately from the regulatory status of the underlying compound.
Retatrutide, Tirzepatide and Semaglutide: A Simple Summary
The differences can be simplified into three levels.
Semaglutide
Semaglutide primarily works through the GLP-1 receptor.
It represents the single-pathway approach in this comparison and has extensive clinical research behind it.
Tirzepatide
Tirzepatide targets both GLP-1 and GIP receptors.
Its dual mechanism distinguishes it from traditional GLP-1-only compounds.
Retatrutide
Retatrutide targets GLP-1, GIP and glucagon receptors.
This three-pathway mechanism is the main reason it has attracted attention as an investigational triple agonist.
Which One Is the Most Advanced?
From a research and regulatory perspective, these compounds are at different stages.
Semaglutide has an extensive clinical history and is approved for several medical uses.
Tirzepatide also has substantial clinical evidence and is approved for specific indications.
Retatrutide remains investigational and is being evaluated through clinical research.
Therefore, it would be misleading to discuss all three as though they have the same regulatory status.
Why Are Triple-Agonist Peptides Being Studied?
The broader direction of peptide research is moving towards understanding whether several metabolic pathways can be influenced simultaneously.
Instead of focusing exclusively on one receptor, researchers are examining combinations that may influence several interconnected biological systems.
Retatrutide is one of the most prominent examples of this approach.
Its GLP-1, GIP and glucagon activity gives researchers an opportunity to study how these pathways interact when targeted by a single molecule.
This does not mean that multi-receptor compounds will necessarily replace single- or dual-receptor approaches. Different mechanisms may ultimately have different applications depending on their safety, effectiveness and individual patient factors.
Final Thoughts
Retatrutide, semaglutide and tirzepatide are often mentioned together, but their mechanisms are clearly different.
Semaglutide = GLP-1
Tirzepatide = GLP-1 + GIP
Retatrutide = GLP-1 + GIP + glucagon
That final addition of glucagon receptor activity is what makes retatrutide particularly interesting from a research perspective.
The term “GLP-3” is commonly used as an informal description of this three-pathway mechanism, but retatrutide remains the actual name of the investigational compound.
Ultimately, comparing these compounds requires more than looking at the number of receptors they target. Their clinical evidence, safety profiles, regulatory status and individual trial results all matter.
As research into multi-receptor peptides continues, retatrutide provides an interesting example of how scientists are exploring increasingly sophisticated approaches to metabolic signalling.
